Monthly Archives: July 2017

http://www.lslog.com/vaccines-provide-a-boost-for-glaxosmithkline-sanofi-and-merck-in-second-quarter-financials/Vaccines provide a boost for GlaxoSmithKline, Sanofi and Merck in second-quarter financials

Vaccines provide a boost for GlaxoSmithKline, Sanofi and Merck in second-quarter financials

Vaccines provide a boost for GlaxoSmithKline, Sanofi and Merck in second-quarter financials For three of the world’s top four vaccine companies, sales growth churned along in the second quarter as […]

http://www.lslog.com/fda-advances-two-more-herceptin-biosims-this-time-from-amgen-and-teva-as-roche-braces-for-impact/FDA advances two more Herceptin biosims—this time from Amgen and Teva—as Roche braces for impact

FDA advances two more Herceptin biosims—this time from Amgen and Teva—as Roche braces for impact

FDA advances two more Herceptin biosims—this time from Amgen and Teva—as Roche braces for impact Herceptin biosimilars are coming for Roche in the U.S., and Monday, a pair of them […]

http://www.lslog.com/news-of-note-kites-car-t-new-flex-ceo-invivo-trial-delay/News of Note—Kite’s CAR-T; New Flex CEO; InVivo trial delay

News of Note—Kite’s CAR-T; New Flex CEO; InVivo trial delay

News of Note—Kite’s CAR-T; New Flex CEO; InVivo trial delay Here’s Monday’s shot of biopharma news of note. Source: FierceMedicalDevices News News of Note—Kite’s CAR-T; New Flex CEO; InVivo trial […]

http://www.lslog.com/abbvie-scores-surprisingly-good-q2-results-but-pipeline-worries-persist/AbbVie scores surprisingly good Q2 results but pipeline worries persist

AbbVie scores surprisingly good Q2 results but pipeline worries persist

AbbVie scores surprisingly good Q2 results but pipeline worries persist July has been a tough month for AbbVie, marked by a stinging patent loss on its megablockbuster Humira and a […]

http://www.lslog.com/soon-shiongs-nantcell-in-356m-deal-for-underperforming-cytrx-cancer-drug/Soon-Shiong’s NantCell in $356M deal for underperforming CytRx cancer drug

Soon-Shiong’s NantCell in $356M deal for underperforming CytRx cancer drug

Soon-Shiong’s NantCell in 6M deal for underperforming CytRx cancer drug NantCell has paid $13 million up front to license CytRx’s orphan cancer drug aldoxorubicin. Source: FierceMedicalDevices News Soon-Shiong’s NantCell in […]

http://www.lslog.com/still-reeling-from-cyberattack-merck-warns-some-drug-supplies-may-be-delayed/Still reeling from cyberattack, Merck warns some drug supplies may be delayed

Still reeling from cyberattack, Merck warns some drug supplies may be delayed

Still reeling from cyberattack, Merck warns some drug supplies may be delayed Merck & Co., one of the victims of the Petya cyberattack last month, has yet to fully restore […]

http://www.lslog.com/anaptysbios-chief-scientific-officer-moyle-heads-for-the-exit/AnaptysBio's chief scientific officer Moyle heads for the exit

AnaptysBio's chief scientific officer Moyle heads for the exit

AnaptysBio’s chief scientific officer Moyle heads for the exit The chief scientific officer of antibody specialist AnaptysBio, Matthew Moyle, has tendered his resignation just over a year after joining the […]

http://www.lslog.com/servier-licenses-galapagos-phase-1-osteoarthritis-drug/Servier licenses Galapagos' phase 1 osteoarthritis drug 

Servier licenses Galapagos' phase 1 osteoarthritis drug 

Servier licenses Galapagos’ phase 1 osteoarthritis drug  Servier has licensed an osteoarthritis drug from Galapagos. The French drugmaker opted in to the program and handed over another slice of the […]

http://www.lslog.com/broad-scientists-show-how-1-bad-gene-takes-a-toll-on-5-vascular-diseases/Broad scientists show how 1 bad gene takes a toll on 5 vascular diseases

Broad scientists show how 1 bad gene takes a toll on 5 vascular diseases

Broad scientists show how 1 bad gene takes a toll on 5 vascular diseases Migraines, coronary artery disease, high blood pressure—they may seem like different diseases but they all share […]

http://www.lslog.com/astrazeneca-merck-team-up-on-lynparza-combos-in-collaboration-worth-up-to-8-5b/AstraZeneca, Merck team up on Lynparza combos in collaboration worth up to $8.5B

AstraZeneca, Merck team up on Lynparza combos in collaboration worth up to $8.5B

AstraZeneca, Merck team up on Lynparza combos in collaboration worth up to .5B Cancer drug Lynparza has been a bright spot for AstraZeneca amid generic competition for its blockbuster Crestor […]